Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Statistics
Share Statistics
Denali Therapeutics has 145.22M shares outstanding. The number of shares has increased by 1.83% in one year.
Shares Outstanding | 145.22M |
Shares Change (YoY) | 1.83% |
Shares Change (QoQ) | 0.9% |
Owned by Institutions (%) | 75.5% |
Shares Floating | 125.71M |
Failed to Deliver (FTD) Shares | 7.28K |
FTD / Avg. Volume | 0.63% |
Short Selling Information
The latest short interest is 7.97M, so 5.54% of the outstanding shares have been sold short.
Short Interest | 7.97M |
Short % of Shares Out | 5.54% |
Short % of Float | 6.4% |
Short Ratio (days to cover) | 7.03 |
Valuation Ratios
The PE ratio is -7.93 and the forward PE ratio is -7.82. Denali Therapeutics's PEG ratio is -0.06.
PE Ratio | -7.93 |
Forward PE | -7.82 |
PS Ratio | 0 |
Forward PS | 2.3 |
PB Ratio | 2.73 |
P/FCF Ratio | -9.22 |
PEG Ratio | -0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Denali Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.46, with a Debt / Equity ratio of 0.03.
Current Ratio | 8.46 |
Quick Ratio | 8.46 |
Debt / Equity | 0.03 |
Debt / EBITDA | -0.09 |
Debt / FCF | -0.12 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-1M |
Employee Count | 422 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | -68K |
Effective Tax Rate | 0.02% |
Stock Price Statistics
The stock price has increased by -28.96% in the last 52 weeks. The beta is 1.46, so Denali Therapeutics's price volatility has been higher than the market average.
Beta | 1.46 |
52-Week Price Change | -28.96% |
50-Day Moving Average | 18.51 |
200-Day Moving Average | 23.1 |
Relative Strength Index (RSI) | 39.68 |
Average Volume (20 Days) | 1.16M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -487.34M |
Net Income | -422.77M |
EBITDA | -487.34M |
EBIT | n/a |
Earnings Per Share (EPS) | -2.57 |
Balance Sheet
The company has 174.96M in cash and 42.29M in debt, giving a net cash position of 132.67M.
Cash & Cash Equivalents | 174.96M |
Total Debt | 42.29M |
Net Cash | 132.67M |
Retained Earnings | -1.54B |
Total Assets | 1.37B |
Working Capital | 762.23M |
Cash Flow
In the last 12 months, operating cash flow was -347.69M and capital expenditures -15.91M, giving a free cash flow of -363.61M.
Operating Cash Flow | -347.69M |
Capital Expenditures | -15.91M |
Free Cash Flow | -363.61M |
FCF Per Share | -2.21 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
DNLI does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for DNLI is $32.5, which is 136.2% higher than the current price. The consensus rating is "Buy".
Price Target | $32.5 |
Price Target Difference | 136.2% |
Analyst Consensus | Buy |
Analyst Count | 17 |
Scores
Altman Z-Score | 5.74 |
Piotroski F-Score | 2 |